According to filings with the U.S. Securities and Exchange Commission, Waypoint Bio has raised $20,000,000.00 in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Amplify Partners, General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, Hummingbird Ventures.

About Waypoint Bio
Waypoint Bio is a biotechnology company focused on developing next-generation cell therapies for solid tumors. The company says it uses a proprietary spatial pooled screening technology and a lab-in-the-loop approach to design and optimize these therapies. It is headquartered in New York City and emerged from stealth in 2024. Waypoint Bio has raised funding from leading biotech and tech investors, including a reported $14.5 million seed round, and it has assembled a scientific advisory board of drug R&D and cancer experts. The company also notes that its technology may have broader drug discovery applications beyond cancer, including Treg therapies for autoimmune diseases.

To learn more, visit https://www.waypointbio.com/
Linkedin: https://www.linkedin.com/company/waypoint-bio/

Contact:
Xinchen Wang, Chief Executive Officer
https://www.linkedin.com/in/xinchen-wang-52ab4789/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.